**PI3Kδ/γ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature**

Evgeni Efimenko,1* Utpal P. Davé,2* Irina V. Lebedeva,1 Yao Shen,3 Maria J. Sanchez-Quintero,4 Daniel Diolaiti,1 Andrew Kung,1 Brian J. Lannutti,5 Jianchung Chen,1 Ronald Realubit,3 Zoya Niatsetskya,1 Vadim Ten,1 Charles Karan,3 Xi Chen,6 Andrea Califano,3 and Thomas G. Diacovo1,7

1Department of Pediatrics, Columbia University Medical Center, New York, New York, 10032, USA. 2Division of Hematology/Oncology, Indiana University School of Medicine and the IU Simon Cancer Center, Indianapolis, Indiana 46202. 3Department of Systems Biology, Columbia University, New York, New York, 10032, USA. 4Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA. 5Oncternal Therapeutics. San Diego, CA 92130. 6Department of Public Health Sciences, University of Miami, Miami Florida, 33136, USA. 7Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, 10032, USA.

* contributed equally

**Running title:** Interplay between PI3Kδ/γ and NOTCH1 in Lmo2-driven T-ALL

**Key Words (5):** T-ALL, GSI, PI3Kγ/δ, cMYC, NOTCH1

**Financial support**

This research is supported by National Cancer Institute grant R01CA169162-01 (T.G. Diacovo), Department of Veterans Affairs (I01BX001799, U.P.D.), the Vanderbilt Ingram Cancer Center (P30 CA68485) (U.P. Davé).

---

This is the author's manuscript of the article published in final edited form as:

Correspondence

Thomas Diacovo, MD
Columbia University
1130 St. Nicholas Ave, Room 924
New York, NY 10032
Tel: 212-851-4683
E-mail: td2142@cumc.columbia.edu

Conflict of Interest Disclosure The authors declare no potential conflicts of interest

Text word count: 4,882
Text abstract count: 226
Number of figures: 7, and 5 Supplementary Figures
Number of tables: 3 Supplementary Tables
Abstract

PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110\(\gamma\) and p110\(\delta\) play a major role in the development and progression of PTEN null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using a Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aberrantly upregulated, we now demonstrate that the combined activities of PI3K\(\delta/\gamma\) have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3K\(\delta/\gamma\) or a \(\gamma\)-secretase inhibitor (GSI) reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3K\(\delta/\gamma\) activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3K\(\delta/\gamma\) inhibition in the context of NOTCH1 and cMYC signaling.
Introduction

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease characterized by frequent relapse, resistance to chemotherapy, and reduced survival as compared to B-precursor ALL (1). Consistent with most lymphoid malignancies, tumor development and disease progression depend upon deregulation of an oncogene(s) and/or tumor suppressor genes that permit unchecked proliferation and resistance to programmed cell death. Chromosomal translocations driven by T-cell receptor-regulatory elements occur frequently in T-ALL, resulting in aberrant expression of a select group of transcription factor oncogenes such as \textit{TAL1}, \textit{LMO1}, \textit{LMO2}, \textit{TLX1}, and \textit{TLX3} (2-4). These gene rearrangement events are typically accompanied by constitutive NOTCH1 signaling due to mutations within its heterodimerization (HD) and C-terminal proline-, glutamic acid-, serine-, and threonine-rich (PEST) domains, causing ligand-independent activation and increased stability of the \(\gamma\)-secretase cleaved intracellular domain (ICN1) (5, 6). Subsequent nuclear translocation of ICN1 stimulates transcription of downstream target genes such as \textit{HES1}, \textit{DTX1}, and \textit{MYC}, the latter being an essential mediator of NOTCH1 signaling (7, 8). cMYC is a known master transcription factor that regulates genes essential for cell metabolism, proliferation and survival (9, 10).

Aberrant activation of the PI3K/AKT pathway has also been implicated in the oncogenic transformation and tumor progression of T-ALL, and is associated with aggressive biological features, drug resistance and poor prognosis (11-13). In the majority of cases this results from a loss or reduced function of the phosphatase and tensin homolog (PTEN) tumor suppressor, which limits levels of PIP\(_3\) generated by class I PI3Ks (14). Interestingly, NOTCH1 has also been reported to indirectly regulate this
signaling pathway due to its ability to alter PTEN expression, which has been implicated in inducing GSI resistance in T-ALL by switching “oncogene addiction” (15). However, other studies have shown that PTEN status does not always correlate with GSI responsiveness, and that NOTCH1 and PI3K/AKT pathways may work in concert to promote tumor growth and survival (16, 17).

Previously, we have demonstrated the importance of the class I PI3K isoforms p110γ and p110δ in T cell development and their ability to cooperate as non-classical oncogenes in supporting leukemogenesis in the absence of negative regulation by PTEN (18, 19). This was further evidenced by our observations that a highly selective dual PI3Kγ/δ inhibitor CAL-130 significantly reduced disease burden, prolonged survival of mice with established PTEN null T-ALL, and induced apoptosis in human T-ALL tumor cells with aberrant PI3K/AKT signaling. Yet, it remains to be determined whether PI3Kγ/δ regulate transcriptional pathways typically associated with activated NOTCH1 (e.g. cMYC). Investigations along these lines are essential for establishing whether p110-selective small molecule inhibitors could synergize or substitute for GSIs in the treatment of T-ALL. Indeed, the variable antitumor effects of GSIs reported in phase I clinical trails would suggest that such an approach is warranted (20, 21). To this end, we evaluated the molecular and genetic interplay between these pathways using the Lmo2-driven mouse model of T-ALL where both PI3K/AKT and NOTCH1 are activated (22-23). Additionally, gene set enrichment and pathway analyses were used to determine if these disparate pro-oncogenic pathways controlled similar genes and transcriptional regulators that are determinants of the disease signature associated with T-ALL.
Materials and Methods

Mice

Cohorts of CD2-Lmo2 and Gt(Rosa)26Sor<sup>tm13(Cag-Myc, -CD2*)Rsky/J;Lck-cre/Pten<sup>fl/fl</sup>, both on C57BL/6J background, were monitored for the onset of leukemia (19, 22, 25). Experiments were performed in accordance with guidelines set forth by the Institutional Animal Care and Use Committee of Columbia University. Animals with established T-ALL received either the dual PI3Kδ/γ inhibitor CAL-130 (10 mg/kg every 8 hours; Calistoga Pharmaceuticals) (19) or the γ-secretase inhibitor dibenzazepine (DBZ; 10 µmol/kg IP daily; Tocris) (26) for a total of 7 days (27). Kaplan-Meier survival and statistical analyses were performed using GraphPad Prism Version 6.0 software. Values were considered significant at P < 0.05.

Primary leukemia samples and cell lines

Cryopreserved human T-ALL samples were provided by St. Jude Children's Research Hospital and Vanderbilt University Medical Center after appropriate IRB review. All samples were collected with informed consent. Murine CD2-Lmo2 T-ALL cell lines 03007 and 03027 were generated as previously described (23). In brief, they were generated in the Davé lab (Vanderbilt University) from T-cell leukemia that arose in transgenic B6.CD2-Lmo2 mice. Once established in culture, aliquots of cells were banked in liquid nitrogen and samples obtained for this study in 2014. The cell lines were identified and then confirmed immediately before use by their immunophenotype and by T-cell receptor Jβ rearrangement.
Retroviral transduction of murine cell line

Plasmid pMSCV-IRES-mCherry and pMSCV-cMyc-IRES-mCherry were kindly provided by the laboratory of Dr. Riccardo Dalla-Favera (Columbia University, NY, NY). Retroviruses were produced in ecotropic packaging cell line 293T Platinum-E according to manufacturer’s instructions (Cell Biolabs Inc). Viral transduction was performed using the RetroNectin® (Takara) and spinoculation method as previously described (28).

Mutation detection

Sequencing of the Notch1 and Pten genes was performed on primary mouse T-ALL cells by PCR using Pfu DNA polymerase (Stratagene) with primers specific for exon 34, and exons 3 through 7, respectively.

FACS

Preparation, staining, and detection of cell surface and cytoplasmic proteins in primary T-ALL cells and murine T-ALL cell lines were performed as previously described (19).

Western blot analysis

Cell lysates were prepared on ice in M-PER Mammalian Protein Extraction reagent (Pierce) containing a cocktail of protease and phosphatase inhibitors (19). Lysates were subjected to SDS-PAGE, transferred to PVDF membrane (Immobilon-P, Millipore), and membranes probed by overnight incubation (4°C) with appropriate primary antibodies.
Bound antibodies were visualized with HRP-conjugated secondary antibodies and ECL chemistry (SuperPico West, Pierce).

**Drug synergy and cell viability studies**

Murine CD2-Lmo2 T-ALL cell lines 03007 and 03027 were plated at optimal density into 384-well tissue culture plates (Greiner 781080) employing the Cell::Explorer automation system (PerkinElmer). CAL-130 or the GSI CompE (ENZO Biochem) (29) (was added using HP D300 Digital Dispenser, and drug activity measured at 60 hours using Cell Titer Glo (Promega). The standard reference model of Bliss independence was employed for the results analysis (30).

Cell lines were also grown in 6 well plates and individually treated with DMSO, CAL-130, IC87114 (Calistoga) (31) CompE for 72 hours. Proliferation and cell death were determined by cell counting with trypan blue and by staining with PI (BD Biosciences) followed by flow cytometric analysis, respectively. For primary murine and human T-ALL samples, cells were harvested from thymi of diseased animals and plated with MS5-DL1 stromal cells in the presence of recombinant IL-7 and FLT-3 (mouse) or recombinant IL-7, FLT-3 and SCF (human). T-ALL cell viability following 72 hours of drug treatment was assessed using the BD Cell Viability kit (BD Biosciences) coupled with fluorescent counting beads as previously described (19). After 72 hours of treatment, absolute number of cells in DMSO control was set to 100%.

**Mitochondria isolation and respiration studies**
Mitochondria were isolated from murine T-ALL cells treated with DMSO or CAL-130 (2.5 µM, 12 h) and respiration analyzed in TRIS-MOPS buffer using Clark’s type electrode (Hansatech, UK) as described (32).

**OCR measurements**

Murine *CD2-Lmo2* T-ALL cell lines treated with CAL-130 (2.5µM, 12 h), CompE (1µM, 48 h) or vehicle (DMSO) were centrifuged and directly suspended in XF assay medium (Seahorse Biosciences) supplemented with 10 mM glucose (Sigma-Aldrich) and 10 mM sodium pyruvate (Invitrogen). For primary *CD2-Lmo2* T-ALL tumors, cells were grown on MS5-DL1 stromal cells in the presence of recombinant IL-7 and FLT-3 (mouse) for 24 h before the addition of DMSO, CAL-130 (2.5 µM, 12 h) or CompE (1µM, 48 h). Tumor cells were then disrupted by pipetting, filtered through a 40 µm strainer to separate from the stromal cells, and centrifuged and suspended in XF assay medium (Seahorse Biosciences) supplemented with 10 mM glucose (Sigma-Aldrich) and 10 mM sodium pyruvate (Invitrogen). Primary tumors or tumor cell lines were added to a XF24 cell culture microplate coated with poly-L-Lysine (Sigma-Aldrich). After 30 minutes at 37°C, OCR was measured using a XFe24 Analyzer (Seahorse Biosciences) after serial injections of oligomycin (1µM), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.75 µM), rotenone (1 µM) and antimycin A (1µM). Coupling efficiency, as a measure of the fraction of basal mitochondrial OCR used for ATP synthesis, was assessed by the decrease in respiration on inhibiting ATP synthase with oligomycin. Cell respiratory control ratio is the ratio of the uncoupled OCR (rate after FCCP injection) to OCR in the presence of oligomycin. Spare respiratory capacity was measured by the ratio
of the uncoupled OCR to the basal rate. Experiments were performed using at least 3 biological replicates and all values were internally normalized (33).

**Glucose Uptake Assessment**

Murine *CD2-Lmo2* T-ALL cell lines cells treated as described were resuspended in glucose-free RPMI-1640 medium containing 1% fetal calf serum (FCS) and 150 µM 2-NBDG (Life Technologies), incubated for 10 min at 37°C, washed with ice-cold PBS and analyzed using flow cytometry. Apigenin (100µM, 30 min treatment), an inhibitor of Glut1 expression, was used as a positive control.

**Microarray procedure**

A representative murine *CD2-Lmo2* derived T-ALL cell line (03007) was treated with DMSO (0.6%) or CAL-130 (2.5 µM; 10 h) or CompE (1 µM; 48 h). Biological triplicates were performed with each experimental condition and gene expression profiling performed by Expression Analysis, Inc. using the Affymetrix Mouse Genome 430 array (#901570). Microarray data were then normalized using the Robust MultiChip Averaging (RMA) algorithm as implemented in the Bioconductor package Affy (34). A modified *t*-test was used in Bioconductor Limma package to identify differentially expressed probe sets between each drug treatment group and control group (35). The *P*-values from Limma analysis were adjusted by Benjamini and Hochberg method to control false discovery rate (FDR) and genes were ranked to identify top 50 up and 50 down regulated genes for each treatment condition (36).
Statistical analyses

Results are expressed as mean ± SEM for a minimum of 3 independent experiments. Statistical analysis was performed using either the Student unpaired t-test or two-way ANOVA followed by Bonferroni post-test. P values < 0.05 were considered significant. Further detailed statistical analysis of the microarray data and information on experimental methods can be found in supplemental materials available on the Molecular Cancer Therapeutics Web site.
Results

*Lmo2*-driven T-ALL is defined by constitutive activation of PI3K/AKT and NOTCH1 pathways

Disease penetrance was 100% with a median survival rate of 227 days in *CD2-Lmo2* transgenic mice (Fig. 1A). Tumor cells displayed high levels of both phosphorylated AKT (Thr308 and Ser473) and intracellular NOTCH1 (ICN) with activation of downstream targets (Fig. 1B); all tumors expressed the p110γ and p110δ catalytic domains of class I PI3Ks (Fig. 1C). Of note, the majority of *Lmo2*-driven T-ALL lacked expression of PTEN, acquired Notch1 mutations within the PEST domain (Supplementary Table S1) and had evidence of upregulation of the Notch1 target genes such as *Deltex1* (~4-fold; Fig. 1D). Moreover, the majority of circulating blasts had an immunophenotype characteristic of NOTCH1-induced T-ALL in mice: CD8 single positive or CD4/CD8 double positive with high expression of CD25 (Fig. 2A and B). Thus, the *CD2-Lmo2* transgenic animal model of T-ALL provided an ideal system to determine whether the combined activities of PI3Kδ/γ regulate similar or distinct oncogenic programs typically associated with NOTCH1 activation.

PI3Kδ/γ blockade or GSI reduces leukemia burden and prolongs survival

To determine the reliance of *Lmo2*-driven T-ALL on the PI3K/AKT versus NOTCH1 pathway, we treated diseased animals with either the dual PI3Kδ/γ inhibitor CAL-130 (10 mg/kg every 8 hours) or the potent γ-secretase inhibitor DBZ (10 μmol/kg per day) for 7 days. Previously we have shown that CAL-130 is highly selective for the p110γ and
p110δ catalytic domains of class I PI3Ks by virtue of its ability to (1) yield an immunologic phenotype similar to that of mice lacking both p110 isoforms when administered to WT animals, and (2) significantly reduces tumor burden and prolong survival in mice that develop PTEN null T-ALL (19). Despite NOTCH1 activation, all mice had a rapid response to the dual PI3Kδ/γ inhibitor as evidenced by a reduction in circulating blasts and presence of apoptotic cells 4 days post treatment (detected sub-G₀ population after propidium iodide (PI) staining) (Fig. 2A). Administration of DBZ also reduced disease burden (Fig. 2B) and resulted in a similar prolongation in survival: median of 27 days for DBZ-treated versus 29 days for CAL-130 treated animals (Fig. 2C, \( P = 0.64 \)).

In order to investigate the direct effects of PI3K/AKT and NOTCH1 inhibition on tumor cell proliferation and survival, we performed in vitro co-culture of primary leukemic blasts from mice and human T-ALLs using MS5-DL1 stromal cells (19). Consistent with in vivo results, primary T-ALL cell viability was significantly reduced in the presence of either CAL-130 or the γ-secretase inhibitor CompE (Fig. 3A, Supplementary Fig. S1A and S1B, and Supplementary Table S1) while the viability of stromal cells was not affected by either compound.

We next evaluated the effects of these inhibitors alone or in combination using two representative T-ALL cell lines, designated 03007 and 03027, which were derived from diseased CD2-Lmo2 transgenic animals (23). Consistent with results obtained with primary tumors, treatment of either cell line with CAL-130, but not the p110δ selective inhibitor IC87114, had a cytostatic effect and induced cell death within 24 hours based on PI staining (Fig. 3B and Supplementary Fig. S1C). The effects of CompE were similar
albeit delayed (Fig. 3C and Supplementary Fig. S1D). To determine whether the combination of CAL-130 and CompE would be synergistic in nature, we used a high-throughput cell viability screen based on cellular ATP detection and the Bliss independence model to quantify the degree of synergy between the pathways (30). Excess over Bliss (EoB) was calculated as the difference between the observed effect and the predicted response; a 5-10% EoB response was considered as weak, 10-20% as moderate, and over 20% was considered as strong synergism. Results indicate that CAL-130 (2.5 µM) in combination with CompE did not yield a synergistic effect in either cell line, suggesting redundancy in the NOTCH1 and PI3K/AKT pathways in Lmo2-driven T-ALL (Supplementary Fig. S2).

**PI3Kδ/γ regulate cMYC expression independently of NOTCH1**

NOTCH1 directly regulates cMYC expression, which governs an oncogenic program supporting T-ALL cell growth and survival (7,8). Accordingly, CompE blocked NOTCH1 activation in Lmo2-driven T-ALL cell lines and also reduce protein levels of cMYC, albeit at distinct time points (24 hours and 48 hours, respectively) (Fig. 3D and Supplementary Fig. S1E). In contrast to the delayed effects associated with GSI, dual inhibition of PI3Kδ/γ activity abolished cMYC protein but not transcript expression within 12 hours of treatment (Fig. 3D and 3E). Importantly, CAL-130 was still able to inhibit activation of AKT (phosphorylation of Thr308 and Ser473) and its downstream targets such as glycogen synthase kinase-3β (GSK3β), the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and the ribosomal protein p70 S6 kinase (p70 S6K) (19), which play a major role in cell cycle progression and tumor cell
proliferation (Fig. 3F and Supplementary Fig. S1F). Of note, blockade of PI3Kδ/γ activity or GSI abrogated the expression of the anti-apoptotic effectors MCL-1 and phospho-BAD (S136) and lead to upregulation of pro-apoptotic BIM (Supplementary Fig. S3A and S3B), with > 50% of CAL-130 treated cells becoming apoptotic by 24 hours in contrast to those treated with CompE as determined by flow cytometry (sub-G1) (Supplementary Figs. S3C-F). In contrast, the majority of effects of CompE were not observed until 48 hours.

In order to confirm that loss of cMYC protein expression is essential for CAL-130 or CompE-induced tumor cell death, we generated an Lmo2-driven murine T-ALL line with constitutive cMYC expression. Indeed, over expression of this oncogene permitted continued tumor cell growth despite incubation with either inhibitor. Moreover, cMYC protein levels remained constant in contrast to cells expressing vector alone (Fig. 4A-F). To further demonstrate that down regulation of cMYC is essential for the anti-tumorigenic effects CAL-130 and that it may exert this effect independent of NOTCH1 activation, we crossed Gt(Rosa)26Sor^{tm13(CAG-MYC, -CD2*)Rsky/J} mice that overexpress cMyc with Lck-cre/Pten^{fl/fl} mice that lack Pten. Previously we have shown that T-ALL that develops in PTEN-null mice is exquisitely sensitive to the dual PI3Kγ/δ inhibition (19). In contrast, T-ALL with enforced cMYC expression was resistant to CAL-130 treatment (10 mg/kg every 8 hours for 7 days) and showed continued expansion of circulating blasts (Ki67+/Thy1.2+ population) and lack of PI-staining (Fig. 4G).
PI3Kδ/γ and NOTCH1 have overlapping gene regulatory networks in Lmo2-driven T-ALL

To better understand the genetic basis by which PI3Kδ/γ and NOTCH1 regulate tumor progression in Lmo2-driven T-ALL, we generated gene expression signatures based on disease phenotype and drug treatment. Global gene expression profiles were obtained in triplicate from tumor cells cultured in the presence of CAL-130 (2.5 µM), CompE (1 µM), or DMSO. Drug treated cells were harvested at time points known to affect cMYC expression (12 hours and 48 hours, respectively). A Venn diagram was created to illustrate the overlap in genes altered by either PI3Kδ/γ blockade (red circle) or GSI (green circle) using a false discovery rate (FDR) of 0.0005 as cut off (Fig. 5A). Of note, ten-fold more genes were affected following PI3Kδ/γ blockade and included the majority (~62%) of genes altered by GSI monotherapy, a highly significant finding (Fisher’s exact test, P < 2.2×10^{-16}). Heat maps were also generated from complete linkage hierarchical cluster analyses of statistically significant changes in gene expression associated with drug treatment versus vehicle control (Fig. 5B). In the case of PI3Kδ/γ blockade, down-regulated genes also included those involved in cMYC-regulated cellular metabolism and/or metabolic reprogramming such as the glycine-serine biosynthetic pathway (e.g. Phgdh, FDR = 6×10^{-8}; Shmt1, FDR = 8.2×10^{-8}; Shmt2, FDR = 6.2×10^{-8}, folate metabolism (e.g. Mthfd1, FDR = 6.04×10^{-8}), glycolysis (e.g. Hk-2, FDR = 5.4×10^{-8}), nucleotide metabolism (Ak4, FDR = 2.3×10^{-8}) and mitochondrial proline metabolism and synthesis (Pycr1, FDR = 3.1×10^{-7}) (37-41). As expected, gene expression profiling of CompE-treated cells demonstrated significant downregulation of canonical NOTCH1 target genes including Hes1 (FDR = 1.1×10^{-7}), Hey1 (FDR = 2.6×10^{-8}), and Deltex1
(FDR = 4.4×10^{-6}), as well as modulating the expression of genes involved in glycolysis (e.g. Slc2a3, FDR = 4.14×10^{-6}; Hk2, FDR = 1.68×10^{-5}) and nucleotide metabolism (e.g. Ak4, FDR=1.66×10^{-3}) (42).

We next defined a murine T-ALL disease signature by ranking all genes based on their differential expression in T-ALL samples compared to wild type murine thymocytes. To determine the contribution of PI3Kγ and NOTCH1 to the overall disease signature, we performed a gene set enrichment analysis (GSEA) of the 200 most transcriptionally activated and repressed genes following treatment with either CAL-130 or CompE in differentially expressed genes. Although both drugs significantly inverted the T-ALL disease signature, underscoring the importance of these signaling pathways in maintaining the leukemic phenotype (Fig. 5C), the enrichment was much more significant with CAL-130 (normalized enrichment score (NES) of -5.8 (P < 0.0001) for CAL-130 versus NES of -2.6 (P = 0.006) for CompE. To show that treatment of murine cells is highly consistent with treatment of human cells, we assessed whether the top 200 most differentially expressed genes following CompE treatment of murine T-ALL cells were significantly enriched in human-to-mouse mapped genes differentially expressed following CompE treatment of human cells (Fig. 5D). To accomplish this goal, we integrated data from seven distinct dataset representing human T-ALL cells treatment with CompE (7). Analysis confirms that results from drug treatment of Lmo2-driven murine T-ALL are relevant to human T-ALL.

Previously, we have shown the existence of Master Regulator (MR) proteins responsible for causally (i.e., physically) regulating the transcriptional state of a cancer
cell (43). As such, their activated and repressed targets are highly enriched in genes that are over- and under-expressed in tumor cells, respectively, and can thus be efficiently identified by analyzing a regulatory network that represents the transcriptional targets of every protein using the VIPER (Virtual Proteomics by Enriched Regulon) algorithm (44). VIPER is an extension of the Master Regulator Inference algorithm (MARINa) (45), which supports analysis of MR proteins on an individual sample basis. Such an analysis has helped elucidate novel mechanisms of tumorigenesis, progression, and drug sensitivity in glioma, leukemia, lymphoma, prostate and breast cancer, among others. As MR protein activity efficiently recapitulates overall tumor state and drug response, we first identified key T-ALL-specific MR proteins and then assessed whether compound treatment could effectively reverse their activity. MR proteins were inferred by VIPER analysis of a previously assembled, genome-wide T-ALL-specific regulatory network (interactome) using a signature of a Lmo2-driven murine T-ALL cell line (7) compared to wild type murine thymocytes. This interactome was previously used to successfully elucidate the Mechanism of Action (MoA) of small molecule compounds targeting human T-ALL pathways (7). The ViPER algorithm was then used to compute the activity of each of the top 40 T-ALL MR proteins following drug perturbation. This was accomplished by computing the enrichment of their regulons (i.e., the set of their transcriptional targets), as represented in the interactome, in genes differentially expressed following drug treatment (drug signature). Although the gene signatures for the two drugs overlapped significantly (P < 6 x 10^{-13}, Fisher exact test), ~3-fold more T-ALL MRs were reverted by CAL-130 compared to GSI CompE (Fig. 5E and Supplementary Table S2; NES < -1.96 and P < 0.05). Of note, Lyl1, Tal1 and Hhex were not affected by
CAL-130 according to our analysis. We also performed GSEA of ∼4,500 annotated gene sets collected from Molecular Signatures Database (MSigDB) on the CAL-130 and CompE induced gene signatures to study the perturbed pathways (46). Although CAL-130 altered many of the same genes as compared to CompE, it had stronger effects on pathways regulated by PML (originally identified as a tumor suppressor in acute promyelocytic leukaemia) (NES 2.57 and P < 0.01 vs. NES 0.82 and P = 0.41), EDF1 (NES -3.58 and P < 0.005 vs. NES -0.53 and P = 0.6) and IRF9 (NES 3.18 and P < 0.005 vs. NES 0.07 and P = 0.944). Thus, CAL-130 treatment recapitulated majority of mechanism of action of CompE, while reversing the activity of a large number of additional master regulators and pathways associated with the T-ALL tumor cell state.

To access drug effects on cMYC activity, we analyzed published microarrays of human T-ALL (47) and used GSEA to compute the enrichment of cMYC-regulated genes differentially expressed following CAL-130 or CompE treatment (Fig. 5F and Supplementary Table S3). Although genes regulated by cMYC were observed in both drug treatment signatures (P < 10^{-3}), CAL-130 treatment had a greater effect in terms of reversing the global expression of cMYC targets (NES of -6.23), compared to CompE (NES of -5.10). Of note, ∼74% of genes regulated by cMYC were in the top 1,000 genes in the CAL-130 treated gene expression signature as compared to ∼42% in the CompE treated gene signature (Supplementary Table S3).

**PI3Kγ/δ and NOTCH1 differentially modulate metabolic and mitochondrial pathways in leukemic cells**
To better assess the functional categories represented by the set of genes altered in response to the inhibitors, we performed pathway analysis using DAVID (48). A highly conservative threshold ($P < 1 \times 10^{-5}$) was used to identify the top down-regulated genes in CAL-130 or CompE treated $Lmo2$-driven T-ALL cells. In the case of PI3Kδ/γ blockade, there was a significant enrichment in functional categories related to cellular metabolism and most interestingly, pathways that regulate mitochondrial activity (Fig. 6A and 6B). CompE treatment not only altered similar metabolic pathways including those related to carbohydrate, nucleotide, pyruvate and TCA (Fig. 6C and Supplementary Fig. S4A and S4B), but also reduce glucose uptake in T-ALL tumor cells as observed for CAL-130 (Fig. 6D and Supplementary Fig. S5A); it did not, however, appear to affect genes that directly regulate mitochondrial function (7, 42, 49).

As aforementioned, blockade of PI3Kγ/δ activity preferentially altered genes that affect mitochondrial activity, such as those involved in the electron transport chain and oxidative phosphorylation (Fig. 7A and Supplementary Fig. S4C). Consistent with this observation, CAL-130 but not CompE significantly reduced in situ oxygen consumption rates (OCRs), ATP levels and spare respiratory capacity, the latter indicating that PI3Kγ/δ inhibition limits the ability of tumor cell lines and primary tumor cells to respond to stress or metabolic challenge (Fig. 7B-E and Supplementary Fig. S5B-H). Further evidence to support these observations was provided by directly studying mitochondria isolated from CAL-130 treated tumor cells. Indeed, a robust inhibition of resting and phosphorylating respirations rates in purified mitochondria were observed suggesting that the alterations in genes encoding the respiratory chain complexes I (e.g. $Ndufa12$), II (e.g. $Sdhb$), and III (e.g. $Cyc1$) were functionally significant (Fig. 6B and
7F). Our experiments also suggested dysregulation of complex IV as evidenced by the marked depression of mitochondrial respiration with TMPD-ascorbate as substrate (50). Of note, CAL-130 treatment affected the expression of mitochondrial protein serine hydroxymethyl transferase (SHMT2; Figure 7F, insert). SHMT2 is a key enzyme in the serine / glycine synthesis pathway that plays a critical role in the metabolic reprogramming in cancer and is a transcriptional target of cMYC (51). Thus, PI3Kγ/δ inhibition not only affects major metabolic pathways that support tumor homeostasis but also affects the bioenergetics of T-ALL cells.
Discussion

Cumulative evidence indicates that the PI3K/AKT and NOTCH1 pathways not only contribute to the malignant transformation of T cell progenitors but also play a major role in regulating the growth, metabolism, and survival of T-ALL. Here, we explored the interdependence of these oncogenic pathways in promoting tumor cell maintenance, which has profound implications for the development of a rational therapeutic strategy to treat this aggressive hematologic malignancy. It is for this reason that we chose the Lmo2-driven transgenic mouse model of T-ALL that is characterized by the spontaneous accumulation of several oncogenic mutations in T cell precursors, resulting in the co-activation of PI3K/AKT and NOTCH pathways. In the context of this model, we now provide evidence that (1) although there is no preferential addiction of tumor cells to either pathway, PI3Kδ/γ blockade appears to exert a more rapid and potent effect on tumor cells than GSI, and (2) there is a lack of synergy between PI3K/AKT and NOTCH1 in supporting tumor cell proliferation and survival.

Previous studies have demonstrated that NOTCH1 can indirectly impact on the activity of the PI3K/AKT pathway by controlling a transcriptional network that regulates PTEN expression in leukemic T cells (15). Indeed, this mechanism is believed to be responsible for bypassing the requirement for aberrant NOTCH1 signaling that normally supports tumor cell growth and metabolism. In contrast, our studies indicate that NOTCH1 does not regulate PI3Kδ/γ activity or PTEN expression, suggesting that these pathways can function independently of one another. This is exemplified by the lack of correlation between activation status of either pathway and the ability of primary mouse
or human T-ALL cells to respond to treatment with CompE or CAL-130. That said, they do appear to control similar oncogenic networks that are indispensible for tumor cell maintenance. Results indicate a genetic underpinning for these observations as evidenced by the considerable overlap in genes regulated by both signaling pathways, including cMYC. The latter was confirmed by the ability of constitutively expressed cMYC to reverse the effects of either inhibitor. Collectively, these data demonstrate that PI3Kδ/γ can support a NOTCH1-independent pathway of cMYC activation in T-ALL, which may account for similar reduction in cell growth and survival but lack of synergistic effect observed in response to CAL-130 and/or CompE (52).

Why then does PI3Kδ/γ blockade appear to exert a more rapid and potent anti-leukemic effect than inhibition of NOTCH1 by GSI? Gene expression profiling and pathway analysis based on DNA microarrays of drug treated Lmo2-driven T-ALL provided possible answers. On a global scale, CAL-130 treatment had a greater effect on altering the disease signature compared to CompE, as demonstrated by the reversal of top master regulators (e.g. HNRNPAB, Tp53, PA2G4, ASH2L and SNAPC5) and affects on pathways (e.g. PML, EDF1, and IRF9) associated with the CD2-Lmo2 T-ALL tumor cell state. This was consistent with the ability of CAL-130 to down regulate a 10-fold greater number of genes at an early time point. Interestingly, the majority of altered genes are known to support cellular metabolism and/or the metabolic reprogramming implicated in tumor progression, including those involved in serine/glycine metabolism, polyamine synthesis, and glycolysis. Indeed, the ability of cancer cells to alter their metabolism is essential to support the increased energy demands associated with rapid tumor growth. Germane to this study is the ability of the PI3K/AKT pathway to act as a master regulator
of aerobic glycolysis and cellular biosynthesis that critically relies on mitochondrial bioenergetics (53, 54). In fact, the shift from oxidative to more glycolytic metabolism is one of the most common changes found in tumor cells. Although our results clearly demonstrated that PI3Kγ/δ blockade or GSI significantly reduced glucose uptake in leukemic cells, only the former was able to rapidly alter mitochondrial function. Indeed, we noted that genes encoding proteins involved in oxidative phosphorylation were uniquely susceptible to CAL-130, including those essential for the mitochondrial respiratory chain complex formation (FDR < 0.005). Consistent with this observation was the robust inhibition of mitochondrial resting and phosphorylating respirations rates. This finding is of particular interest as enhancement in the bioenergetics properties of tumor cells is thought to be a prerequisite for survival.

Overall, our results suggest the existence of a regulatory circuit linking NOTCH1 and PI3K/AKT signaling, with cMYC serving as a crucial node of convergence that intertwines but does preferentially support the activity of either pathway. Moreover, we provide new insights into the mechanism(s) by which the combined activities of PI3Kδ/γ contribute to the maintenance of T-ALL and how pharmacological blockade of these two isoforms exerts a more rapid and pronounced effect on tumor cell proliferation than GSI, yet can yield similar rates of survival of diseased animals. This involves regulating transcriptional pathways and genes typically associated with NOTCH1, as well as distinct metabolic and bioenergetic pathways essential for tumor progression and survival. These results provide a rationale for the combined targeting of p110γ and p110δ catalytic domains of class I PI3Ks in T-ALL where NOTCH and/or PI3K/AKT pathways are dysregulated.
Acknowledgements

We thank Juan Carlos Zuniga-Pflucker for providing the MS5-DL1 cells, Andrew Nicholson, Anastasiya Egorova, and Anna Binyamin for genotyping and animal husbandry, and St. Jude Children’s Research Hospital for providing primary T-ALL cells from patients.
References


Figure legends

Figure 1. PI3K/AKT and NOTCH1 pathways are co-activated in Lmo2 driven T-ALL in mice. A, Kaplan-Meier survival curves for CD2-Lmo2 transgenic animals. Representative immunoblots of the primary T-ALL cells from diseased mice showing protein expression of PTEN and cMYC as well as AKT and NOTCH1 activation state (B), and expression of p110 catalytic subunits of class I PI3K (C). D, Expression levels of Notch1 and its target Deltex1 in primary murine tumors compared to wild-type (WT) DN3 thymocytes as determined by qRT-PCR (n = 7). ***, P < 0.0001; ns = not significant.

Figure 2. Combined PI3Kδ/γ blockade or GSI reduces tumor burden and prolongs the survival of mice with Lmo2-driven T-ALL. A and B, Flow cytometric analysis of disease status in CD2-Lmo2 transgenic mice immediately before and 4 days and 7 days after initiating treatment with either the dual PI3Kδ/γ inhibitor CAL-130 (A; 10 mg/kg every 8h) or theγ-secretase inhibitor DBZ (B; 10 µmol/kg daily) for 7 days. Tumor response to drug treatments was confirmed by changes in circulating blasts (Thy1.2+/Ki67+) and evidence of propidium iodide (PI)-staining. C, Kaplan-Meier survival curves for CD2-Lmo2 mice with T-ALL treated with either CAL-130 or DBZ for 7 days. The latter only included animals that received the full course of drug, P = 0.64 (log-rank test).
Figure 3. PI3Kδ/γ inhibition promotes tumor cell death irrespective of NOTCH1 activation status. A, Analyses of primary CD2-Lmo2 mouse T-ALL tumor cell viability in the presence of increasing concentrations of CAL-130 or CompE for 72 h. B-C, Proliferation and survival analysis of a representative Lmo2-driven T-ALL tumor cell line (03007) cultured in the presence of increasing concentrations of CAL-130 (B) or CompE (C) for 72 h. Data represent mean ± SEM (n = 3 in triplicate). Statistical significance was determined by Student’s t test for drug treated cells relative to control. *, P < 0.01; **, P < 0.001; ***, P < 0.0001; ns (not-significant). D, Immunoblots of PTEN and cMYC expression as well as NOTCH1 activation state in a representative CD2-Lmo2 T-ALL cell line (03007) cultured in the presence of CAL-130 (6, 12, and 24 hours) or CompE (24 and 48 hours). E, Expression levels of cMyc in the identical tumor cell line after 12 h of treatment with CAL-130 (2.5 µM) as determined by qRT-PCR (n = 3). F, Immunoblots depicting AKT and the activation state of its downstream effectors in the same cell line at the indicated duration of treatments.

Figure 4. Overexpression of cMYC results in resistance to CAL-130 and GSI treatments. A-D, FACS dot plots (A and B) and viability bar graphs (C and D) of a representative CD2-Lmo2-driven T-ALL cell line (03007) transfected with mCherry-expressing empty or WT cMYC vector and treated with CAL-130 (72 hours), CompE (27, 96 and 120 hours) or DMSO control. Data represent mean ± SEM (***, P < 0.0001; n = 3, t test). cMYC protein expression in the same cells treated with CAL-130 (E) or CompE (F) for 24 and 48 hours, respectively. G, Flow cytometric analysis of disease status in two representative (n = 5) Gt(ROSA)26Sor^{tm13(CAG-MYC,-CD2*)Rsky}/J; Lck-cre/Pten^{fl/fl} mice immediately before and 7 days after initiating treatment with dual PI3Kγ/δ inhibitor.
CAL-130 (10 mg/kg every 8h) for 7 days. Tumor drug response was determined by assessing for changes in circulating blasts (Thy1.2\(^+\)/Ki67\(^+\)) and propidium iodide (PI)-staining.

**Figure 5.** Blockade of PI3K\(\gamma/\delta\) activity reverses the oncogenic signature of *Lmo2*-driven T-ALL. 

- **A**, Venn diagram comparing the number and overlap of genes altered by PI3K\(\gamma/\delta\) blockade (red circle) or GSI (green circle) using FDR < 0.0005 as cut-off. Gene expression profiling was performed on triplicate samples of the CD2-*Lmo2* T-ALL cell line (03007) treated with either CAL-130 (2.5\(\mu\)M, 10 hours) or CompE (1\(\mu\)M, 48 hours) as compared to DMSO control. 

- **B**, Heat map representation of the top 100 differentially expressed genes (FDR < 0.00001) between DMSO and CAL-130 or CompE treated tumor cells. The scale bar shows color-coded differential expression, with red and blue indicating higher and lower levels of expression, respectively. Red arrows denote cMYC-regulated genes. 

- **C**, Enrichment of top 100 activated and repressed genes from *Lmo2*-driven T-ALL disease signature (T-ALL versus WT mouse thymocytes) on the CAL-130 (top) and CompE (bottom) activity gene signature. Repressed genes are shown in blue, and over-expressed genes are shown in red. 

- **D**, Comparison of GSI treatment signature for tumor cells (top 200 up and down regulated genes) on the consensus GSI perturbational signature obtained from the expression profiles (GSE5827) of seven human T-ALL cell lines treated with DMSO or CompE. 

- **E**, Enrichment of top 40 activated and repressed T-ALL master regulator TFs (as inferred by ViPER based on the *Lmo2*-driven T-ALL versus WT murine thymocyte signature) on the CAL-130 (top) and
CompE (bottom) activity signature, respectively. F, Enrichment of cMYC-regulated genes on the sorted CAL-130 (top) and CompE (bottom) treatment gene signature.

**Figure 6.** PI3Kδ/γ and NOTCH1 regulate metabolic pathways that contribute to the oncogenic programming of Lmo2-driven T-ALL. A, Functional annotation of top 297 genes down regulated (P < 0.00001) in a CAL-130 (2.5 µM, 10 h) treated CD2-Lmo2 T-ALL cell line (03007) using DAVID. Pathways with Benjamini Hochberg corrected P < 0.05 are shown. B, Heat map of metabolism-related gene expression profiles after CAL-130 or vehicle (DMSO) treatment (in triplicate). Colored bar denotes pathways annotated in A, and red and blue indicate high and low levels of gene expression, respectively. C, Summary of GSEA performed on the ranked genes according to the ratios of transcripts from DMSO, CAL-130 (2.5 µM, 10 h) or CompE (1µM, 48 h) treated cells. Six metabolic gene sets with P < 0.01 and a false discovery rate (FDR) of <0.05 (represents threshold) were considered significant. D, Inhibition of glucose uptake by PI3Kγ/δ blockade or NOTCH1 inhibition. Histograms (upper) and mean fluorescence intensity (MFI, lower) of 2-NBDG incorporation into tumor cells treated with DMSO, CAL-130 (2.5 µM, 14 h) or CompE (1µM, 72 h). Apigenin (100µM, 30 min treatment), an inhibitor of Glut1 expression, was used as a positive control. Data represent mean ± SEM (**, P < 0.01, *** P < 0.001 relative to DMSO; n = 3, t test).
**Figure 7.** PI3Kδ/γ regulate distinct bioenergetic pathways that contribute to the oncogenic programming of *Lmo2*-driven T-ALL. **A,** Summary of mitochondrial GSEA analysis performed on the ranked genes according to the ratios of transcripts from DMSO, CAL-130 (2.5 µM, 10 h) or CompE (1µM, 48 h) treated cells. Gene sets with a *P* < 0.01 and a false discovery rate (FDR) of < 0.05 (represents threshold) were considered significant. **B** and **C,** Oxygen consumption rates (OCR) in the same cell line treated with DMSO vs. CAL-130 (2.5µM) for 12 hours (**B**) or DMSO vs. CompE (1µM) for 48 hours (**C**) under basal conditions and in response to the indicated mitochondrial inhibitors. Changes after oligomycin and FCCP application are indicative for respiration linked to ATP synthesis and the maximal respiratory capacity, respectively. **D** and **E,** ATP production and spare respiratory capacity in CAL-130 (**D**) or CompE (**E**) treated tumor cells. Data represent mean ± SEM (***, *P* < 0.0001, *n* = 3, *t* test). **F,** Respiration of mitochondria isolated from a *CD2-Lmo2* T-ALL cell line (03007) following exposure to CAL-130 (2.5 µM, 12 hours) or DMSO and supported with two different substrates: complex-I dependent glutamate-malate (upper panel) or complex-IV linked substrate, TMPD-ascorbate (lower panel). Red and black tracings denote drug and DMSO treated cells, respectively. The points of initiation of resting, phosphorylating and uncoupled respirations are indicated (arrows). The values of the phosphorylating respiration rates (PRR) are provided. Schematic substrate-dependent changes in electron supply for mitochondrial respiratory chain is presented above each tracing. Insert shows western blot analysis for the mitochondria expressed SHMT2 protein in treated tumor cells.
Figure 1

A. Survival curve for CD2-Lmo2 (n=20) cells over time.

B. Western blot analysis:
- NOTCH ICN
- PTEN
- cMYC
- α-Tubulin
- p-AKT (S473)
- p-AKT (T308)
- Total AKT
- p-GSK-3β (S9)
- Total GSK-3β
- p4E-BP1 (T37/46)
- Total 4E-BP1

C. Western blot for p110α, p110β, p110γ, and p110δ with β-ACTIN loading control.

D. Bar graph showing expression fold change for Notch1 and Deltex1:
- CD2-Lmo2 tumor cells
- WT thymocytes

Significance:
- ** ns p<0.001
Figure 2

A) WBC (x10^6 / ml)

<table>
<thead>
<tr>
<th></th>
<th>Day 0</th>
<th>Day 4</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>188</td>
<td>4.3</td>
<td>14.2</td>
</tr>
<tr>
<td>IgG control</td>
<td>95</td>
<td>0.6</td>
<td>14</td>
</tr>
<tr>
<td>WT control</td>
<td>12.5</td>
<td>0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>CD2-Lmo2</td>
<td>10.5</td>
<td>0.1</td>
<td>17.5</td>
</tr>
</tbody>
</table>

B) WBC (x10^6 / ml)

<table>
<thead>
<tr>
<th></th>
<th>Day 0</th>
<th>Day 4</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>34.4</td>
<td>1.1</td>
<td>4.3</td>
</tr>
<tr>
<td>IgG control</td>
<td>36.1</td>
<td>7.2</td>
<td>9.6</td>
</tr>
<tr>
<td>WT control</td>
<td>18.7</td>
<td>0.68</td>
<td>8.5</td>
</tr>
<tr>
<td>CD2-Lmo2</td>
<td>10.3</td>
<td>0.1</td>
<td>16</td>
</tr>
</tbody>
</table>

C) Survival %

- No drug (n=15)
- CAL-130 Treated (n=8)
- DBZ Treated (n=7)

$P=0.64$